Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: A neurochemical study

Annals of the New York Academy of Sciences

Volumn 1155, Issue , 2009, Pages 309-315

  Di Matteo, Vincenzo ^a   Pierucci, Massimo ^a   Benigno, Arcangelo ^b   Crescimanno, Giuseppe ^b   Esposito, Ennio ^a   Di Giovanni, Giuseppe ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

6 hydroxydopamine (6 OHDA); Corpus striatum; Dopamine (DA); Nitric oxide (NO); Parkinson's disease (PD); Substantia nigra pars compacta (SNc)

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 7 NITROINDAZOLE; DOPAMINE; MOLSIDOMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; EXPERIMENTAL RAT; MALE; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; RAT; STRIATONIGRAL DEGENERATION;

RATTUS;

EID: 61649122828     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03678.x     Document Type: Conference Paper

References (40)

1. Bian, K. & F. Murad. 2003. Nitric oxide (NO)-biogeneration, regulation, and relevance to human diseases. Front. Biosci. 8 : 264 278.
2. Feifer, A. & S. Carrier. 2008. Pharmacotherapy for erectile dysfunction. Expert Opin. Investig. Drugs 17 : 679 690.
3. Thatcher, G.R., B.M. Bennett & J.N. Reynolds. 2006. NO chimeras as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 3 : 237 245.
4. Akyol, O. et al. 2004. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18 : 377 390.
5. Snyder, S.H. 1993. Janus faces of nitric oxide. Nature 364 : 577.
6. Esposito, E., V. Di Matteo & G. Di Giovanni. 2007. Death in the substantia nigra: A motor tragedy. Expert Rev. Neurother. 7 : 7677 7697.
7. Di Matteo, V. et al. 2006. 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: An in vivo microdialysis study. Ann. N. Y. Acad. Sci. 1089 : 462 471.
8. Del Bel, E. et al. 2007. Nitric oxide system and basal ganglia physiopathology. In The Basal Ganglia Pathophysiology: Recent Advances. G. Di Giovanni, Ed 129 158. Transworld Research Network. Kerala, India.
9. Gomes, M.Z., R. Raisman-Vozari & E.A. Del Bel. 2008. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res. 1203 : 160 169.
10. Di Giovanni, G. 2008. Will it be possible to prevent nigral neurodegeneration? CNS Neurol. Disord. Drug Targets 7 : 28 44.
11. Jellinger, K. 1989. Pathology of Parkinson's disease. In Handbook of Experimental Pharmacology. D.B. Calne, Ed Vol. 8 : 47 112. Springer. Berlin.
12. Scherman, D. et al. 1989. Striatal dopamine deficiency in Parkinson's disease: Role of aging. Ann. Neurol. 26 : 551 557.
13. Di Giovanni, G. 2007. The Basal Ganglia Pathophysiology: Recent Advances. Transworld Research Network. Kerala, India.
14. von Bohlen und Halbach, O., A. Schober & K. Krieglstein. 2004. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog. Neurobiol. 73 : 151 177.
15. Di Giovanni, G. et al. 2007. Biochemical and therapeutic effects of antioxidants in the treatment of Parkinson's disease. In The Basal Ganglia Pathophysiology: Recent Advances. G. Di Giovanni, Ed 253 283 Transworld Research Network. Kerala, India.
16. Jenner, P. et al. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32 : S82 S87.
17. Simonian, N.A. & J.T. Coyle. 1996. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36 : 83 106.
18. Mark, R.J. et al. 1997. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68 : 255 264.
19. Dexter, D.T. et al. 1991. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 : 1953 1975.
20. Barc, S. et al. 2001. Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors. Neurosci. Lett. 314 : 82 86.
21. Watanabe, H. et al. 2004. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: An immunohistological study. Eur. Neuropsychopharmacol. 14 : 93 104.
22. Przedborski, S. et al. 1996. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. 93 : 4565 4571.
23. Haik, K.L. et al. 2008. 7-nitroindazole attenuates 6-hydroxydopamine- induced spatial learning deficits and dopamine neuron loss in a presymptomatic animal model of Parkinson's disease. Exp. Clin. Psychopharmacol. 16 : 178 189.
24. Paxinos, G. & C. Watson. 1986. The Rat Brain in Stereotaxic Coordinates. Second Edition. Academic Press. New York.
25. Soto-Otero, R. et al. 2000. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: Potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 74 : 1605 1612.
26. Kirik, D., C. Rosenblad & A. Bjorklund. 1998. Characterization of behavioural and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 : 259 277.
27. Simola, N., M. Morelli & A.R. Carta. 2007. The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res. 11 : 151 167.
28. Castagnoli, K. et al. 1997. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 10 : 364 368.
29. Boireau, A. et al. 2000. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 39 : 1016 1020.
30. Thomas, B., K.S. Saravanan & K.P. Mohanakumar. 2008. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem. Int. 52 : 990 1001.
31. Betarbet, R., T.B. Sherer & J.T. Greenamyre. 2002. Animal models of Parkinson's disease. Bioessays 24 : 308 318.
32. Deumens, R., A. Blokland & J. Prickaerts. 2002. Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 : 303 317.
33. Antunes, F. et al. 2005. Redox interactions of nitric oxide with dopamine and its derivatives. Toxicology 208 : 207 212.
34. Riobo, N.A. et al. 2002. The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic. Biol. Med. 32 : 115 121.
35. Hornykiewicz, O. 1989. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease - A critical analysis of the neurochemical evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry 13 : 319 328.
36. Zigmond, M.J., T.G. Hastings & R.G. Perez. 2002. Increased dopamine turnover after partial loss of dopaminergic neurons: Compensation or toxicity? Parkinsonism Relat. Disord. 8 : 389 393.
37. Lang, A.E. & A.M. Lozano. 1998. Parkinson's disease: First of two parts. New Engl. J. Med. 339 : 1044 1053.
38. Kurosaki, R. et al. 2002. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol. Res. 24 : 655 62.
39. Kwon-Soo, H.A. et al. 2003. Nitric oxide prevents 6-hydroxydopamine- induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J. 17 : 1036 1047.
40. Choi, Y.B. & S.A. Lipton. 2000. Redox modulation of the NMDA receptor. Cell Mol. Life Sci. 57 : 1535 1541.